Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin + trilaciclib + paclitaxel/carboplatin + anti‑PD-(L)1 for first-line advanced squamous NSCLC
ChiCTR2400094918Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar, trilaciclib, paclitaxel and carboplatin in Pulmonary squamous cell carcinoma, sponsored by Shanghai Chest Hospital. Primary endpoints: 12-month progression-free survival and Objective response rate (ORR). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
endostartrilaciclibpaclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2400094918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094918.